Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A retrospective review of all recorded cases of osteosarcoma diagnosed and treated in Manitoba from 1930 to 1977 was carried out. There were 95 patients (64 males, 31 females). The peak age was 10 to 19 years. The most common sites of osteosarcoma were the femur (38 patients), tibia (14 patients), humerus (13 patients) and pelvis (9 patients). The survival rate (excluding parosteal and periosteal types) was 28% at 2 years and 16% at 5 years. Patients who were operated upon had a somewhat better prognosis than those who had radiotherapy. Initial results of chemotherapy are encouraging. Patients with distal limb tumours had a better prognosis than those with more proximal neoplasms. Patients with tumour secondary to Paget's disease and to irradiation did poorly, those with parosteal and periosteal osteosarcoma did better. Thirteen patients had 31 thoracotomies for pulmonary metastases; their average duration of survival after this procedure was 9.3 months.
 ...
PMID:Osteosarcoma in Manitoba: review of 95 patients. 29 64

A 9-year-old male German Shepherd Dog with osteogenic sarcoma involving the right humerus was treated by scapulohumeral disarticulation and adjuvant chemotherapy. Doxorubicin was used, at a dosage of 30 mg/m2 of body surface. Chemotherapy was unsuccessful, and 4 months after surgery, the dog developed multiple metastases of osteogenic sarcoma in the appendicular skeleton, a metastatic pattern rarely observed with primary bone tumors.
 ...
PMID:Multiple skeletal metastases of osteogenic sarcoma in a dog. 29 98

Levels of alkaline phosphatase were measured in the primary tumor of 26 patients with osteosarcoma. One of seven patients with a tissue alkaline phosphatase level less than 0.6 microM/min/mg developed pulmonary metastases. In contrast, 16 or 17 patients with a tissue alkaline phosphatase level greater than 0.6 microM/min/mg developed pulmonary metastases. It thus appears that tissue alkaline phosphatase levels of primary osteosarcomas are strongly correlated with prognosis (p less than .01).
 ...
PMID:Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. 29 11

Data from 106 patients with osteosarcoma who developed metastases during treatment were analyzed for prognostic factors for postmetastic survival time. Patients diagnosed in 1971 or later received more intensive chemotherapy and had significantly longer postmetastatic survival time than those diagnosed in 1970 or earlier (P = 0.002). Patients whose metastasis occurred 13 or more months after diagnosis had signicantly longer postmetastatic survival time than those whose metastasis occurred during the first 12 months after diagnosis (P = 0.005). Life-table regression analysis revealed an interaction between "year of diagnosis" and "months to metastasis" which provided a postmetastatic survival advantage for those having metastasis after diagnosis over metastasis at diagnosis for patients diagnosed in 1971 or later but not for those diagnosed in 1970 or earlier (P = 0.093).
 ...
PMID:Prognosis after metastases in osteosarcoma. 29 32

For period from 1971 to 1975, 18 cases of osteosarcoma were experienced among 9132 spontaneously hypertensive rats. The onset was at 72 to 145 days of age and death occurred before 423 days of age. The tumors were multiple being distributed in the skull (11 of 14 cases), caudal vertebrae (8 of 14 cases), and fore- and hind-limb. All the tumors were mainly composed of sarcomatous tissue with some osteoid and cartilage. Metastasis was never observed. Serum A1-P levels of tumor bearing animals were 2 times higher than those without tumor. Bronchiectasis and abscess formation of submaxillary lymph nodes were noted in most affected animals.
 ...
PMID:[Multiple osteosarcoma in spontaneously hypertensive rats (author's transl)]. 29 56

The radiologic features of lymph node metastases from osteogenic sarcoma visible on plain films in two patients are described. In one patient the lymph node ossification was visible on presentation and in the other patient it was demonstrated six months after the initial diagnosis. The radiologic pattern in both cases was similar. Deposition of metastatic osteoid tissue in lymph nodes, to such a degree that it can be recognized on plain films, appears to be a distinctly uncommon complication of this malignant neoplasm. It is considered probable that this complication occurs with the osteoblastic type of osteogenic sarcoma. It is suggested that lymphography might be of value in the detection of such metastases at an earlier stage, thus influencing the plan of treatment.
 ...
PMID:Lymph node metastases from osteoblastic osteogenic sarcoma visible on plain films. 29 98

An animal model for human osteosarcoma was established in newborn Syrian golden hamsters by injecting productively infected TE-85 cells (cultured human osteosarcoma cells) adjacent to the femur. Tumors were palpable 10 to 15 days following cell injection and enlarged progresively until the animal died (mean survival time was 36 days). The tumor take was 100% and all animals developed pulmonary metastases. Osteoid and bone were identified in sections of the tumor by light and electron microscopy. Invasion of the marrow spaces and adjacent skeletal muscle by the malignant osteoblasts, anaplastic sarcoma cells and multinucleated giant cells was frequently observed. The tumor was transplantable. TE-85 cell surface antigens were demonstrable by immunofluorescence on the surface of the cells of the induced tumors. The present tumor model had unique immunologic characteristics in that no antibodies were demonstrable in the sera of the tumored animals.
 ...
PMID:A model for human osteosarcoma in hamsters. 29 56

Results of treatment for osteosarcoma of the extremity have been poor with metastases usually causing death within 2 years following diagnosis. Because of the great risk of development of metastases, 20 patients have received adjuvant chemotherapy with Adriamycin, cyclophosphamide and high-dose methotrexate-leucovorin rescue for up to 12 months following amputation for osteosarcoma. Sixteen of these patients are surviving; 11 are free of evident tumor from 6 to 34 months following amputation. Five patients were found to have pulmonary metastases while receiving chemotherapy and three patients developed metastases following completion of chemotherapy. One patient died following her third treatment with high-dose methotrexate-leucorovin rescue. Other toxicity included nausea, vomiting, mucosal ulcerations, infections, hematologic abnormalities, changes in kidney and liver functions tests, and minor coagulation abnormalities. The natural history of osteosarcoma may have been modified by the use of these agents for periods exceeding the median time to predicted detection of pulmonary metastases. Microscopic metastases of some patients were eradicated by this adjuvant chemotherapy. For patients who developed metastases, these metastases were delayed in their time of detection and in their number at the time of detection.
 ...
PMID:Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. 29 29

Four white women who developed osteosarcoma during pregnancy were referred for treatment, 2 prior to delivery and development of metastases, and 2 after delivery and development of metastases. After amputation, these patients received combination chemotherapy with either vincristine-cyclophosphamide or adriamycin-cyclophosphamide followed by high-dose methotrexate with leucovorin rescue. Two patients survived, 1 tumor-free and 1 with bony and soft tissue metastases. Management of pregnant patients with osteosarcoma should include the use of adjuvant systemic chemotherapy to prevent detectable metastases. This treatment should follow amputation or resection and early termination of pregnancy.
 ...
PMID:Osteosarcoma during pregnancy. 30 20

Vincristine (VCR), high-dose methotrexate (MTX), and citrovorum factor (CF) were administered to 12 patients with classic osteogenic sarcoma with local control. Seven patients (58%) are free of pulmonary metastases for 2+-31/2+ years. With a second adjuvant program incorporating adriamycin (VCR, MTX, CF, and adriamycin), 16 of 20 patients are free of pulmonary metastases for 6+-18+ months. Five patients who developed pulmonary metastases were rendered free of disease by surgical resection. The VCR, MTX, and CF program was also administered at weekly intervals to eight patients with pulmonary metastases or unresected primary lesions. Two complete and one partial response were obtained in four patients with pulmonary metastases and three complete and one partial response were obtained in patients with primary lesions. This program was also administered in combination with radiation therapy to four patients who relapsed on conventional VCR, MTX, CF, and adriamycin therapy following surgical resection of pulmonary metastases. They remain free of recurrent disease for 2+-14+ months. There was no alteration in the incidence of toxicity when compared to earlier investigations. The results indicate that the VCR, MTX, and CF program has had a major impact on the management of osteogenic sarcoma.
 ...
PMID:High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II. 30 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>